Article Figures & Data
Tables
Age-Group CRC % (SE) PSA % (SE) Mammograph% (SE)y Note: adjusted for age-group, sex, race/ethnicity, education, income, insurance status, and self-rated health. CRC = colorectal cancer screening (fecal occult blood test <2 years, or flexible sigmoidoscopy <5 years and/or colonoscopy <10 years); PSA = screening prostate specific antigen screening <2 years; mammography = mammography screening <2 years; SE = standard error. 50-54 y 40.3 (0.6) 52.4 (1.0) 78.6 (1.1) 55-59 y 52.8 (0.7) 65.5 (1.1) 83.3 (1.2) 60-64 y 58.5 (0.8) 70.4 (1.2) 80.5 (1.3) 65-69 y 63.1 (0.8) 76.0 (1.2) 80.7 (1.3) 70-74 y 66.0 (0.8) 77.7 (1.0) 77.9 (1.5) 75-79 y 65.6 (0.8) 79.3 (1.1) 77.1 (1.5) ≥ 80 y 60.4 (0.9) 71.8 (1.4) 65.7 (1.8) Age-Group Excellent % (SE) Very Good % (SE) Good % (SE) Fair % (SE) Poor % (SE) Note: adjusted for age-group, sex, race/ethnicity, education, income, insurance status, and self-rated health. SE = standard error. 50-54 y 51.1 (2.0) 49.1 (1.7) 53.7 (1.7) 55.3 (2.8) 58.7 (4.0) 55-59 y 60.6 (2.5) 65.9 (1.8) 66.4 (1.9) 67.7 (3.0) 71.9 (3.5) 60-64 y 69.7 (2.4) 69.2 (2.3) 69.0 (2.2) 74.0 (2.6) 73.1 (3.3) 65-69 y 69.5 (4.3) 79.4 (1.8) 75.0 (1.8) 78.0 (2.5) 78.9 (3.0) 70-74 y 72.9 (3.2) 78.7 (1.9) 79.7 (1.6) 78.3 (2.7) 74.0 (3.1) 75-79 y 78.1 (3.4) 79.7 (2.4) 81.3 (1.7) 79.5 (2.2) 74.6 (3.5) ≥ 80 y 79.6 (3.5) 75.2 (2.6) 71.9 (2.4) 69.6 (3.0) 68.9 (4.4) Age-Group White % (SE) African American % (SE) Other Race % (SE) Multi-Race % (SE) Hispanic % (SE) Refused % (SE) Note: adjusted for age group, sex, race/ethnicity, education, income, insurance status, and self-rated health. CRC = colorectal cancer screening (fecal occult blood test <2 years, or flexible sigmoidoscopy <5 years and/or colonoscopy <10 years); PSA = screening prostate-specific antigen screening <2 years; mammography screening <2 years; SE = standard error. Colorectal cancer screening 50-54 y 40.4 (0.6) 43.2 (2.2) 34.2 (3.9) 38.1 (4.6) 36.0 (2.5) 45.4 (6.2) 55-59 y 52.6 (0.7) 63.1 (2.5) 39.1 (4.6) 64.1 (4.6) 48.0 (3.5) 51.5 (6.8) 60-64 y 60.5 (0.8) 60.8 (3.0) 43.9 (4.8) 55.2 (5.9) 44.6 (3.9) 63.7 (6.5) 65-69 y 65.2 (0.8) 62.3 (2.8) 45.6 (6.4) 56.8 (5.9) 52.2 (3.8) 66.3 (5.8) 70-74 y 68.4 (0.8) 59.2 (3.3) 56.5 (8.1) 62.1 (6.6) 54.2 (4.0) 44.2 (7.0) 75-79 y 67.0 (0.9) 60.1 (4.0) 53.8 (8.0) 66.3 (6.3) 66.1 (4.7) 44.6 (7.8) ≥80 y 62.3 (0.9) 52.1 (4.4) 41.5 (6.6) 67.2 (7.7) 54.9 (6.5) 50.1 (6.1) Prostate-specific antigen screening 50-54 y 50.5 (1.0) 67.8 (3.1) 43.2 (5.6) 44.7 (6.5) 58.2 (3.9) 61.0 (8.9) 55-59 y 64.5 (1.1) 77.3 (3.2) 49.3 (7.4) 63.5 (7.3) 70.9 (4.5) 68.2 (7.3) 60-64 y 71.6 (1.1) 76.7 (4.1) 60.7 (6.0) 63.7 (7.9) 62.2 (6.3) 68.0 (9.6) 65-69 y 77.5 (1.0) 75.3 (4.1) 54.6 (9.7) 66.1 (7.9) 74.4 (5.5) 78.4 (6.1) 70-74 y 78.9 (1.0) 72.8 (4.6) 67.1 (6.7) 77.6 (7.8) 72.0 (7.0) 79.0 (7.0) 75-79 y 80.3 (1.1) 78.9 (4.4) 79.3 (7.3) 75.0 (9.2) 66.2 (6.7) 50.6 10.8) ≥ 80 y 71.9 (1.5) 70.6 (8.2) 68.4 (8.3) 74.3 (9.2) 76.2 (6.6) 58.0 (11.2) Mammography screening 50-54 y 77.5 (1.4) 85.3 (2.3) 67.7 (6.0) 75.2 (7.6) 88.6 (3.1) 59.1 (20.2) 55-59 y 82.4 (1.4) 90.7 (2.2) 81.4 (5.7) 75.8 (6.6) 83.2 (5.4) 91.5 (9.5) 60-64 y 78.8 (1.5) 87.0 (3.5) 84.7 (4.7) 91.7 (4.7) 83.5 (4.9) 93.2 (4.4) 65-69 y 79.8 (1.5) 87.3 (3.0) 84.1 (6.2) 86.7 (5.8) 79.9 (7.5) 64.1 (20.8) 70-74 y 77.6 (1.6) 83.7 (4.1) 75.0 (6.0) 54.7 (8.3) 74.5 (8.3) 82.3(10.8) 75-79 y 75.8 (1.7) 89.0 (3.0) 71.3 (7.8) 53.8 (8.8) 81.4 (6.7) 88.9 (7.7) ≥ 80 y 66.0 (1.9) 60.5 (8.1) 58.0 (8.8) 53.9 (1.9) 69.7 (9.3) 69.8 (12.8)
Additional Files
Supplemental Table and Figure
Supplemental Table: Screening by population characteristics of persons aged 50 to 80 or more years responding to the 2001 behavioral risk factor surveillance system questionnaire; Supplemental Figure: Adjusted predicted cancer screening, by age-group and sex.
Files in this Data Supplement:
- Supplemental data: Table - PDF file, 2 pages, 70 KB
- Supplemental data: Figure - PDF file, 1 page, 73 KB
The Article in Brief
An examination of 3 cancer-screening tests shows that such tests may be underused or overused based on age. Abnormal growths in the colon that can develop into cancer (called adenomatous polyps) are most likely to develop between 55 and 65 years of age. Screening for colorectal cancer, however, is relatively low among 50-year olds and increases with age, reaching its peak among 70- to 74-year-olds. Prostate-specific antigen (PSA) screening for prostate cancer also increases with age, from 50 years old through ages 75 to 79 years, despite the unproved benefit of PSA screening, particularly among men who are 70 years old and older. The rate of screening for breast cancer using mammograms is highest among women 55 to 59 years old and declines after that. Although some guidelines for mammograms do not include women aged 70 years and older, other recommendations suggest that mammograms should be discussed with all women who are expected to live 5 years or more, regardless of age. More research is needed on how age effects cancer screening.